Search This Site




Philadelphia Weekly - The Trouble With Spikol


 

 

 

 

Cost of the War in Iraq
(JavaScript Error)

 

 

« Oh, and also... | Main | "I'm so glad we had this time together..." »

No such thing as a free lunch. Literally.

acomplia_banner.jpg

The cycle continues: Weight-loss med comes out. People freak out and get excited about being thin. They take it and some lose weight. Success stories in the press stoke the excitement. Sales soar. THEN: it comes out that something terrible is happening to people taking the drug. FDA gets pissed. Nightmare scenarios in the press stoke fear. Sales decline. Drug (sometimes) is discontinued.

I think we're at the beginning of that cycle -- or some variation on it -- with the new weight-loss drug Acomplia. The European analog to the FDA has concerns that Acomplia increases the risk of psychiatric symptoms and suicide risk in people who take it, particularly if those people suffer from major depression prior to taking it. When the drug was approved for use in Europe in 2006, depression was the most problematic side effect.

EU Warns of Sanofi Drug

Post a comment

(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)

About

self portrait web final.JPG

Liz Spikol is senior contributing editor of Philadelphia Weekly. She writes the award-winning column The Trouble With Spikol, which began as a chronicle of her struggle with mental illness, and has since expanded into humorous musings on everything from graphic novels to how to use a mop. She also writes the paper's book review column, Lit Gloss. This blog -- named one of the Top 10 Bipolar Blogs of 2007 by PsychCentral -- is about mental illness policy, news, personal journeys and more.